NEU.AX - Neuren Pharmaceuticals Limited

ASX - ASX Delayed Price. Currency in AUD

Neuren Pharmaceuticals Limited

697 Burke Road
Suite 201
Camberwell, VIC 3124
61 3 9092 0480

Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard Spencer Treagus B.Sc., M.B.A., BScMed, MBChB, MPharmMed, MBAExec. ChairmanN/AN/AN/A
Mr. Lawrence GlassChief Science OfficerN/AN/AN/A
Mr. Jonathan Charles PilcherCFO & Company Sec.N/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of drugs for the treatment of chronic neurodevelopmental and neurodegenerative disorders, and acute traumatic brain injury. Its lead product is trofinetide, which has completed Phase II clinical trials for the treatment of Rett syndrome; is in Phase II clinical trials for the treatment of Fragile X syndrome; and conducted Phase II clinical trials for the treatment moderate to severe traumatic brain injury. The company also develops NNZ-2591 that is in preclinical development for the treatment of Phelan-McDermid syndrome. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 1993 and is based in Camberwell, Australia.

Corporate Governance

Neuren Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.